Home
  • Home
  • Resources
  • Diseases
  • Training
  • SYSVAC
    • About
    • Registry
    • E-learning course
  • News
  • Events
  • Network
    • Vision and Mission
    • Steering Committee
    • Map
    • Meetings
    • Join us
  • Home
  • Resources

Resources

Selected

No filters selected.

Type of publications
  • Guidelines (22)
  • NITAG documentation (1442)
  • Reports (54)
  • SAGE documentation (190)
  • Scientific publications (106)
  • Systematic reviews (SYSVAC) (1910)
Topics
Regions
  • Africa (199)
  • Americas (676)
  • Eastern Mediterranean (30)
  • Europe (603)
  • South-East Asia (62)
  • Western Pacific (181)
Countries
  • Algeria (1)
  • Angola (1)
  • Argentina (29)
  • Armenia (2)
  • Australia (93)
  • Bahrain (3)
  • Bangladesh (3)
  • Belgium (69)
  • Benin (5)
  • Bolivia (3)
  • Brazil (4)
  • Burkina Faso (13)
  • Canada (108)
  • Chile (62)
  • China (59)
  • Colombia (1)
  • Comoros (1)
  • Congo (Democratic Republic of) (1)
  • Costa Rica (1)
  • Côte d’Ivoire (17)
  • Denmark (3)
  • Ethiopia (15)
  • Finland (1)
  • France (162)
  • Germany (58)
  • Greece (1)
  • Honduras (14)
  • India (19)
  • Indonesia (5)
  • Iran (Islamic Republic Of) (5)
  • Ireland (17)
  • Israel (2)
  • Italy (5)
  • Japan (3)
  • Kazakhstan (2)
  • Kenya (1)
  • Kyrgyzstan (5)
  • Lebanon (1)
  • Luxembourg (30)
  • Malaysia (1)
  • Mali (3)
  • Malta (1)
  • Mexico (1)
  • Mongolia (1)
  • Morocco (1)
  • Mozambique (37)
  • Nepal (6)
  • Netherlands (44)
  • New Zealand (10)
  • Nicaragua (1)
  • Niger (4)
  • Nigeria (9)
  • Norway (1)
  • Oman (6)
  • Pakistan (2)
  • Peru (2)
  • Russian Federation (1)
  • Senegal (10)
  • Slovenia (7)
  • South Africa (9)
  • South Korea (8)
  • Spain (25)
  • Sri Lanka (3)
  • Sudan (2)
  • Sweden (11)
  • Switzerland (18)
  • Tanzania (United Republic Of) (3)
  • Thailand (9)
  • Togo (1)
  • Tunisia (1)
  • Uganda (23)
  • Ukraine (1)
  • United Arab Emirates (1)
  • United Kingdom (102)
  • United States of America (422)
  • Uruguay (2)
  • Zambia (2)
Diseases
  • Cholera (27)
  • COVID-19 (1092)
  • Dengue (29)
  • Diphtheria (71)
  • Ebola (12)
  • Haemophilus influenzae type B (58)
  • Hepatitis A (58)
  • Hepatitis B (122)
  • Hepatitis C (4)
  • Hepatitis E (1)
  • Herpes zoster (24)
  • HIV / AIDS (1)
  • Human papillomavirus (HPV) (366)
  • Influenza (468)
  • Japanese encephalitis (34)
  • Malaria (18)
  • Measles (100)
  • Meningococcal disease (130)
  • Mpox // Monkeypox (19)
  • Mumps (38)
  • Pertussis (86)
  • Pneumococcal disease (212)
  • Poliomyelitis (57)
  • Rabies (25)
  • Rotavirus (98)
  • Rubella (52)
  • Smallpox (14)
  • Tetanus (48)
  • Tick-borne encephalitis (5)
  • Tuberculosis (60)
  • Typhoid (18)
  • Varicella (55)
  • Yellow fever (23)
  • Zika (1)
Publication date
  • 2023 (12)
  • 2022 (687)
  • 2021 (593)
  • 2020 (375)
  • 2019 (172)
  • 2018 (193)
  • 2017 (252)
  • 2016 (234)
  • 2015 (234)
  • 2014 (195)
  • 2013 (133)
  • 2012 (122)
  • 2011 (111)
  • 2010 (174)
  • 2009 (60)
  • 2008 (44)
  • 2007 (26)
  • 2006 (26)
  • 2005 (17)
  • 2004 (10)
  • 2003 (9)
  • 2002 (6)
  • 2001 (7)
  • 2000 (5)
  • 1999 (2)
  • 1998 (2)
  • 1997 (3)
  • 1996 (1)
  • 1994 (1)
  • 1993 (1)
  • 1991 (1)
  • 1985 (1)
  • 1984 (1)
  • 1963 (1)
Target population
  • Adolescents (421)
  • Adults (742)
  • All age groups (749)
  • Children (309)
  • Healthcare workers (236)
  • Migrants (1)
  • Newborn (260)
  • Older adults (486)
  • Parents/caregivers (157)
  • Pregnant women (170)
  • Risk group (9)
  • Travellers (12)
Available to download in languages
  • English (EN) (1176)
  • French (FR) (405)
  • Spanish (ES) (141)
  • German (DE) (35)
  • Portugese (PT) (34)
  • Dutch (NL) (33)
  • Russian (RU) (27)
  • Arabic (AR) (8)
  • Swedish (SV) (6)
2023 ∙ NACI
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
  • Background paper
  • Canada
  • Pneumococcal disease
Download:
  • EN
2023 ∙ NACI
Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
  • Older adults
  • Adults
  • Recommendation
  • Canada
  • Pneumococcal disease
Download:
  • EN
2023 ∙ NACI
Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
  • Newborn
  • Recommendation
  • Canada
  • Pneumococcal disease
Download:
  • EN
2023
NITAG Maturity Assessment Tool (NMAT)
Download:
  • EN
2023 ∙ Commission Technique des Vaccinations
Vaccination strategy against Covid-19: anticipation of vaccination campaigns in 2023
  • Recommendation
  • France
  • COVID-19
Download:
  • FR
2023 ∙ NACI
Recommendation on Repeated Seasonal Influenza Vaccination
  • All age groups
  • Recommendation
  • Canada
  • Influenza
Download:
  • EN
2023 ∙ ATAGI
ATAGI 2023 booster advice
  • booster dose
  • Recommendation
  • Australia
  • COVID-19
Download:
  • EN
2023 ∙ ATAGI
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
  • Pfizer-BioNTech vaccine
  • Recommendation
  • Australia
  • COVID-19
Download:
  • EN
2023
Updated HPV Technical Dossier on Quadrivalent HPV (Gardasil-4valent) 1-dose Regimen
  • Recommendation
  • Nigeria
  • Human papillomavirus (HPV)
Download:
  • EN
2023 ∙ Conseil Supérieur de la Santé (CSS)
Pneumococcal vaccination in children and adolescents in Belgium
  • Children
  • Adolescents
  • Recommendation
  • Belgium
  • Pneumococcal disease
Download:
  • FR
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • ...
  • Home
  • Resources
  • Diseases
  • Training
  • SYSVAC
  • News
  • Events
  • Network
  • Sign in / Register
National Immunization Technical Advisory Groups
  • Home
  • Resources
  • Diseases
  • Training
  • SYSVAC
  • News
  • Events
  • Network
© 2022

Footer legal info

  • Legal Notice
Subscription to the monthly updates

On the last Wednesday of every month, we send updates about the latest NITAG recommendations in each region, relevant articles related to NITAG work, and other big announcements. Don’t miss them out!

Loading...